Lates News

After a mid-term review, Bristol-Myers Squibb (BMY.N) and Johnson & Johnson (JNJ.N) announced the halt of a crucial late-stage clinical trial testing their experimental anti-thrombotic drug. An independent review found that the study of the drug was unlikely to meet its primary objective in patients with a certain type of heart disease.